PPHLN1: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: PPHLN1

NCBI ID: G51535

PPHLN1

PPHLN1: A Potential Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain, as well as its debilitating effects on physical and mental health, make it difficult for patients to lead fulfilling lives. In addition, the rising burden of healthcare costs associated with managing chronic pain has become a significant challenge for healthcare systems. Therefore, there is a need for new treatments that can provide relief from pain and improve quality of life.

PPHLN1: A Potential Drug Target and Biomarker

The pain pathway is a complex system that involves various cellular and molecular interactions. The imbalance of pain signaling is tightly regulated, and the imbalance between pain perception and pain modulation can lead to chronic pain. ThePPHLN1 gene, located on chromosome 6, has been identified as a potential drug target and biomarker for chronic pain.

PPHLN1: The Potential Drug Target

The PPHLN1 gene encodes for a protein known as pain-associated protein-like (PAPL), which plays a critical role in pain signaling. PAPL is a transmembrane protein that can interact with various pain receptors, including nociceptors and endogenous opioids. PAPL functions as a negative regulator of pain signaling, preventing excessive pain from occurring.

PPHLN1: The Potential Biomarker

In addition to its role in pain signaling, PAPL has also been identified as a potential biomarker for chronic pain. Chronic pain is associated with increased levels of inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6, which can cause inflammation in the central nervous system and local tissues. PAPL has been shown to regulate the activity of these cytokines, limiting their effects on pain perception and persistence.

PPHLN1: The Potential Drug Target and Biomarker in Chronic Pain

The potential drug target for PAPL is its role in modulating pain signaling. Activation of PAPL has been shown to decrease pain sensitivity, while inhibition of PAPL has been shown to increase pain sensitivity. Therefore, drugs that can either activate or inhibit PAPL activity could provide relief from chronic pain.

PPHLN1 has been shown to play a critical role in the development and maintenance of chronic pain. For example, studies have shown that individuals with genetic variants in the PPHLN1 gene are more likely to experience chronic pain. Additionally, individuals with chronic pain have lower levels of PAPL than those without chronic pain.

Conclusion

The PPHLN1 gene has been identified as a potential drug target and biomarker for chronic pain. Its role in pain signaling and its potential as a biomarker for chronic pain make it an attractive target for new treatments. Further research is needed to understand the full potential of PPHLN1 as a drug target and biomarker for chronic pain.

Protein Name: Periphilin 1

Functions: Component of the HUSH complex, a multiprotein complex that mediates epigenetic repression. The HUSH complex is recruited to genomic loci rich in H3K9me3 and is probably required to maintain transcriptional silencing by promoting recruitment of SETDB1, a histone methyltransferase that mediates further deposition of H3K9me3. In the HUSH complex, contributes to the maintenance of the complex at chromatin (PubMed:26022416). Acts as a transcriptional corepressor and regulates the cell cycle, probably via the HUSH complex (PubMed:15474462, PubMed:17963697). The HUSH complex is also involved in the silencing of unintegrated retroviral DNA: some part of the retroviral DNA formed immediately after infection remains unintegrated in the host genome and is transcriptionally repressed (PubMed:30487602). May be involved in epithelial differentiation by contributing to epidermal integrity and barrier formation (PubMed:12853457)

The "PPHLN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPHLN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets